ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax.

1. Planned registration period 4 years 2. Planned surveillance period 5 years and 6 months

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphoma, T-Cell, Peripheral Disease Attributes Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Sex eligibility

All sexes

Study type

Observational

Primary location

Nihon Seimei Hospital

Osaka, 550-0006, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who have been diagnosed with relapsed or refractory PTCL who receive Istodax for the first time.

Exclusion criteria

N/A

Treatment and study plan

Istodax

Drug

Istodax

Primary outcomes

Adverse Events (AEs)

Time frame: Up to approximately 5 years

Number of participants with adverse event

Sponsors and collaborators

Lead sponsor

Celgene

Industry

Registry information

Official study title

ISTODAX® for Intravenous Infusion 10mg Drug Use Results Survey - Relapsed or Refractory Peripheral T-Cell Lymphoma

Important dates

Study start: 2019
Primary completion: 2023
Study completion: 2023
First posted: Nov 15, 2018
Registry last updated: Dec 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed